drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Engineered natural killer cells expressing a chimeric antigen receptor specific for CD123 (IL-3 receptor α), administered intravenously as cellular immunotherapy to eliminate CD123-positive AML/BPDCN cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Engineered natural killer cells expressing a chimeric antigen receptor that binds CD123 (IL‑3 receptor α) on AML/BPDCN cells. CAR engagement activates NK signaling and triggers cytotoxicity (perforin/granzyme release and cytokine secretion), leading to targeted lysis of CD123-positive malignant blasts and stem-like leukemic cells.
drug_name
CD123-targeted CAR-NK cells
nct_id_drug_ref
NCT06006403